Abstract 5-Aminosalicylic acid (5-ASA), the active moiety of sulphasalazine (SASP), was given as a rectal enema to patients with mild to moderate distal ulcerative colitis to determine the minimum effective dosage. A double blind study was carried out using enemas containing 1, 2, or 4 g or 5-ASA or placebo for a one month treatment period. One hundred and thirteen patients with ulcerative colitis attending our outpatient clinic volunteered to participate. Clinical, sigmoidoscopic, and histological assessments were carried out at the beginning of the study and after 15 and 30 days of treatment. Ali patients who received 5-ASA enemas showed significantly better results than those who received a placebo enema (p<0-001) but no difference was detected among the patients receiving differing concentrations of 5-ASA. This study suggests that 1 g 5-ASA (in a 100 ml enema) is a sufficient dosage for patients with a mild to moderate attack of ulcerative colitis.
It has been well established for more than 10 years that sulphasalazine (SASP) works only through one of its components, 5-aminosalicylic acid (5-ASA), which is beneficial through its topical action.' Because of this, rectal enemas containing 5-ASA have become a first line treatment for patients with mild or moderate attacks of left sided ulcerative colitis.' Clinical trials have been carried out using different dosages of 5-ASA in enemas. In the first of these studies, designed to detect the active moiety of SASP, Azad Khan et al' used 700 mg only, which corresponds to the dosage of 5-ASA released in the colon by 2 g of SASP taken orally. Their positive results were equal to those obtained with enemas containing 2 g of SASP.
We subsequently adopted 5-ASA at very high dosages (4 g), 4 believing that the benefits would be dose related, as they are for oral SASP. 7 The results obtained were extremely good and the high dosages of 5-ASA given by rectum did not produce the unwanted effects associated with an equivalent dosage of 5-ASA linked to sulphapyridine given orally.8 In the following years there have been further studies using 5-ASA given at dosages ranging from 1 g to 4 g"' and the results have always been satisfactory. Since the study design was different in each trial, however, it was not possible to compare the data and to establish the lowest dosage with the maximum benefit.
Powell The basic vehicle for the enemas comprised sodium carboxymethylcellulose (1 g), sodium dihydrogen phosphate dodecaidrate (0 125 g), sodium chloride (0 9 g), ascorbic acid (as sodium salt) (0-05 g), gum tragacanth (0 4 g), and water to reach 100 ml of volume. One, 2, or 4 g of purified 5-ASA were put in sealed containers containing 0-01 g, 0-015 g, and 0-03 g of sodium carboxymethylcellulose. The placebo enemas were prepared similarly. In order to ensure the 'blindness' of the study, 0 35 g of lactose (a white powder very similar to the pure 5-ASA) was also placed in containers. The contents of each container were mixed by each patient with the basic vehicle just before use.
The enemas were provided by CHIESI Pharmaceutical Company, Parma, Italy.
Results
The baseline characteristics of patients are given in Table I . The groups were comparable with regard to age and sex distribution, duration of disease, and disease activity.
All the patients completed the study. Only five complained of minor troubles -two in the placebo group and one for each 5-ASA group. These effects were not drug related. Haematological and biochemical tests were within the normal range and stool examinations were negative for pathogens. With regard to the sigmoidoscopic findings, after 15 and 30 days the percentages of patients improved or in remission were 67% and 74%, 67% and 73%; 76% and 79%, 26% and 30% for 1 g, 2 g, and 4 g 5-ASA enemas and placebo respectively.
The percentages showing histological improvement after 15 and 30 days' treatment were 55% and 63% for 1 g 5-ASA, 63% and 70% for 2 g 5-ASA, 69% and 76% for 4 g 5-ASA, and 11% and 15% for placebo.
With regard to all the parameters evaluated, there were no statistical differences between the three groups given 5-ASA enemas. Table II shows a slightly better (statistically insignificant) 
Discussion
This double blind placebo controlled trial was designed to establish the optimum therapeutic dosage of 5-ASA enemas in the treatment of patients with mild to moderate left sided colitis. Three different 5-ASA enema preparations (containing 1, 2, and 4 g) were used, while another group of patients was treated with placebo enemas.
Our results clearly indicate that all the 5-ASA treated patients showed significantly better results than those treated with placebo. These data confirm the value of the topical administration of 5-ASA enemas for distal ulcerative colitis as suggested in previous studies.'.
No statistical differences were detected between the various subgroups of 5-ASA treated patients, so it seems that the topical administration of 5-ASA enemas does not produce a dose dependent therapeutic effect. The findings of this study agree with a previous preliminary study'0 carried out to investigate a possible dosedependent effect of 5-ASA administered as rectal enemas. In our study, the results obtained using a dosage of 4 g further confirm the already postulated lack ofa dose-response effect reported with only two 5-ASA preparations (1 and 2 g). What was speculatively suggested by extrapolating the results ofa small pilot study'0 is substantiated by the data from our prospective controlled study.
The question that needs clarification is why the topical rectal administration of 5-ASA, either as an enema or suppository,'2 does not produce a dose dependent therapeutic effect when at least two studies have shown that oral 5-ASA preparations are effective in a dose dependent way.'1'4 One possible explanation of these contrasting findings could be related to the different distribution of 5-ASA in the colon. Because 
